T1	Participants 86 123	advanced epithelial ovarian carcinoma
T2	Participants 289 385	patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
T3	Participants 408 456	Patients with bidimensionally measurable disease
T4	Participants 957 969	226 patients
T5	Participants 1863 1889	relapse of ovarian cancer.
